XTRA:BAYN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bayer Aktiengesellschaft operates as a life science company worldwide. More Details


Snowflake Analysis

Established dividend payer and fair value.


Similar Companies

Share Price & News

How has Bayer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BAYN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.0%

BAYN

-3.0%

DE Pharmaceuticals

-3.2%

DE Market


1 Year Return

-37.1%

BAYN

1.1%

DE Pharmaceuticals

0.2%

DE Market

Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned 1.1% over the past year.

Return vs Market: BAYN underperformed the German Market which returned 0.2% over the past year.


Shareholder returns

BAYNIndustryMarket
7 Day-4.0%-3.0%-3.2%
30 Day-21.4%-9.2%1.0%
90 Day-30.3%-11.2%-2.9%
1 Year-34.2%-37.1%4.4%1.1%3.4%0.2%
3 Year-56.9%-62.4%22.2%8.2%1.0%-7.8%
5 Year-57.9%-65.0%22.2%1.2%21.1%3.8%

Price Volatility Vs. Market

How volatile is Bayer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bayer undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BAYN (€42.33) is trading below our estimate of fair value (€118.49)

Significantly Below Fair Value: BAYN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BAYN is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.

PE vs Market: BAYN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BAYN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BAYN is good value based on its PB Ratio (1.2x) compared to the DE Pharmaceuticals industry average (6.2x).


Next Steps

Future Growth

How is Bayer forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?

56.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BAYN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: BAYN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BAYN's is expected to become profitable in the next 3 years.

Revenue vs Market: BAYN's revenue (2.1% per year) is forecast to grow slower than the German market (6.1% per year).

High Growth Revenue: BAYN's revenue (2.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BAYN's Return on Equity is forecast to be low in 3 years time (14.7%).


Next Steps

Past Performance

How has Bayer performed over the past 5 years?

-33.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BAYN is currently unprofitable.

Growing Profit Margin: BAYN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BAYN is unprofitable, and losses have increased over the past 5 years at a rate of 33% per year.

Accelerating Growth: Unable to compare BAYN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BAYN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.2%).


Return on Equity

High ROE: BAYN has a negative Return on Equity (-20.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Bayer's financial position?


Financial Position Analysis

Short Term Liabilities: BAYN's short term assets (€32.8B) do not cover its short term liabilities (€36.5B).

Long Term Liabilities: BAYN's short term assets (€32.8B) do not cover its long term liabilities (€51.3B).


Debt to Equity History and Analysis

Debt Level: BAYN's debt to equity ratio (111.1%) is considered high.

Reducing Debt: BAYN's debt to equity ratio has increased from 108.6% to 111.1% over the past 5 years.

Debt Coverage: BAYN's debt is not well covered by operating cash flow (19.4%).

Interest Coverage: BAYN is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Bayer current dividend yield, its reliability and sustainability?

6.61%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BAYN's dividend (6.61%) is higher than the bottom 25% of dividend payers in the German market (1.22%).

High Dividend: BAYN's dividend (6.61%) is in the top 25% of dividend payers in the German market (3.77%)


Stability and Growth of Payments

Stable Dividend: BAYN's dividends per share have been stable in the past 10 years.

Growing Dividend: BAYN's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: BAYN is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: BAYN's dividends in 3 years are forecast to be well covered by earnings (33.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Werner Baumann (58 yo)

4.42yrs

Tenure

€7,461,000

Compensation

Mr. Werner Baumann has been Chairman of Management Board and Chief Executive Officer at Bayer AG since May 1, 2016 and has been its Member of Management Board since January 1, 2010. Since January 1, 2020, ...


CEO Compensation Analysis

Compensation vs Market: Werner's total compensation ($USD8.83M) is above average for companies of similar size in the German market ($USD5.28M).

Compensation vs Earnings: Werner's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Werner Baumann
Chairman of Management Board4.42yrs€7.46mno data
Wolfgang Nickl
CFO & Member of Management Board2.33yrs€3.22mno data
Liam Condon
Member of Management Board & President of Bayer Crop Science Division4.75yrs€4.41mno data
Heiko W. Schipper
Head of Consumer Health Division & Member of Management Board2.58yrs€3.53mno data
Stefan Oelrich
President of Pharmaceuticals Division & Member of the Board of Management1.92yrs€4.03mno data
Bernd-Peter Bier
Head of Accounting and Head of Taxes4.5yrsno datano data
Oliver Maier
Head of Investor Relations3.58yrsno datano data
Gabriel Harnier
Head of Lawno datano datano data
Michael Preuss
Head of Communications4.42yrsno datano data
James Turner
Global Product Directorno datano datano data
Frank Rittgen
Head of Mergersno datano datano data
Peter Müller
Head of Finance for Corporate Center9.17yrsno datano data

4.4yrs

Average Tenure

52yo

Average Age

Experienced Management: BAYN's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Paul M. Achleitner
Member of Supervisory Board18.5yrs€204.00kno data
Wolfgang Plischke
Member of Supervisory Board4.5yrs€275.00kno data
Simone Bagel-Trah
Member of Supervisory Board6.5yrs€137.00kno data
Daniel Hartert
Chairman of Executive Board - Bayer Business Servicesno datano datano data
Petra Reinbold-Knape
Member of Supervisory Board8.5yrs€205.00kno data
Reiner Hoffmann
Member of Supervisory Board14yrs€135.00kno data
Oliver Zühlke
Vice Chairman of Supervisory Board5.25yrs€270.00kno data
Günter Hilken
Chairman of Executive Board - Currentano datano datano data
Horst Baier
Member of Supervisory Board0.50yrno datano data
André van Broich
Member of Supervisory Board8.5yrs€205.00kno data
Michael Schmidt-Kießling
Member of Supervisory Board8.5yrs€137.00kno data
Norbert Winkeljohann
Chairman of Supervisory Board0.50yr€290.00kno data

7.5yrs

Average Tenure

62.5yo

Average Age

Experienced Board: BAYN's board of directors are considered experienced (7.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.


Top Shareholders

Company Information

Bayer Aktiengesellschaft's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bayer Aktiengesellschaft
  • Ticker: BAYN
  • Exchange: XTRA
  • Founded: 1863
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €41.753b
  • Shares outstanding: 982.42m
  • Website: https://www.bayer.com

Number of Employees


Location

  • Bayer Aktiengesellschaft
  • Kaiser-Wilhelm-Allee 1
  • Leverkusen
  • North Rhine-Westphalia
  • 51368
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BAYR.YOTCPK (Pink Sheets LLC)SPON ADR-EACH REPR 1 ORD NPVUSUSDDec 1972
BAYADB (Deutsche Boerse AG)SPON ADR-EACH REPR 1 ORD NPVDEEURDec 1972
BAYAXTRA (XETRA Trading Platform)SPON ADR-EACH REPR 1 ORD NPVDEEURDec 1972
BAYZ.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDJan 1975
0P6SLSE (London Stock Exchange)YesRegistered SharesGBEURJan 1975
BAYNDB (Deutsche Boerse AG)YesRegistered SharesDEEURJan 1975
BAYNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFJan 1975
BAYBIT (Borsa Italiana)YesRegistered SharesITEURJan 1975
BAYNXTRA (XETRA Trading Platform)YesRegistered SharesDEEURJan 1975
BAYERBUSE (Budapest Stock Exchange)YesRegistered SharesHUHUFJan 1975
BAYNDBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBEURJan 1975
BAYN NBMV (Bolsa Mexicana de Valores)YesRegistered SharesMXMXNJan 1975
BAYNWBAG (Wiener Boerse AG)YesRegistered SharesATEURJan 1975
BAY018DB (Deutsche Boerse AG)NPV (NEW)DEEURJan 2018

Biography

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription produ ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 21:00
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.